A revolutionary treatment, retatrutide, is sparking considerable buzz within the Aussie weight management community. Developed by Eli Lilly , this twin GIP and GLP-1 receiver appears to offer more impressive outcomes than existing therapies. Preliminary clinical trials have shown remarkable decre